Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes,Michael J. Mauro,Jorge E. Cortes,Hironobu Minami,Delphine Rea,Daniel J. DeAngelo,Massimo Breccia,Yeow-Tee Goh,Moshe Talpaz,Andreas Hochhaus,Philipp le Coutre,Oliver G. Ottmann,Michael Heinrich,Juan Luis Steegmann,Michael W. Deininger,Jeroen J. W. M. Janssen,François-Xavier Mahon,Yosuke Minami,David T. Yeung,David M. Ross,Martin S. Tallman,Jae H. Park,Brian J. Druker,David Hynds,Yuyan Duan,Christophe Meille,Florence Hourcade-Potelleret,K. Gary Vanasse,Fabian Lang,Dong-Wook Kim

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

2019

Abstract Background Asciminib is an allosteric inhibitor that binds a myristoyl site of the BCR-ABL1 protein, locking BCR-ABL1 into an inactive conformation through a mechanism distinct from those ...

Keywords:

Surgery
Myeloid leukemia
Kinase
Medicine
ABL
Allosteric regulation
Cancer research
Myristoylation
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations